Skip to main content
Year archive

NEUREN PHARMACEUTICALS LIMITED — 2022 filings

All 36 regulatory filings released by NEUREN PHARMACEUTICALS LIMITED (NEU) in 2022, sourced directly from the official regulator.

36 Filings
2022 Period
2022 filings (36)
Filing Released Lang
Neuren submits IND & first patients complete Phase 2 trials 3 pages 298.8KB
Regulatory Filings
2022-12-22 English
Becoming a substantial holder 5 pages 204.0KB
Major Shareholding Notification
2022-12-06 English
Ceasing to be a substantial holder 1 page 93.7KB
Major Shareholding Notification
2022-12-01 English
Change in substantial holding 9 pages 258.7KB
Major Shareholding Notification
2022-11-22 English
Jefferies London Healthcare Conference 2022 presentation 16 pages 1.2MB
Investor Presentation
2022-11-17 English
Q3 2022 quarterly activity and cash flow report 10 pages 375.4KB
Interim / Quarterly Report
2022-10-26 English
Neuren receives US$10 million milestone payment 2 pages 152.4KB
Capital/Financing Update
2022-10-19 English
Investor presentation, 14 September 2022 22 pages 1.4MB
Investor Presentation
2022-09-13 English
Rett Syndrome NDA accepted for Priority Review by FDA 4 pages 221.7KB
Capital/Financing Update
2022-09-12 English
Half Yearly Report and Accounts 15 pages 350.1KB
Interim / Quarterly Report
2022-08-23 English
Half-year shareholder update 5 pages 294.8KB
Interim / Quarterly Report
2022-08-23 English
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS 3 pages 187.9KB
Regulatory Filings
2022-08-07 English
Investor presentation, 8 August 2022 22 pages 1.2MB
Investor Presentation
2022-08-07 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 359.0KB
Interim / Quarterly Report
2022-07-28 English
Acadia submits Rett Syndrome New Drug Application to the FDA 5 pages 318.1KB
Capital/Financing Update
2022-07-18 English
Neuren commences Phase 2 trial of NNZ-2591 in Angelman 2 pages 159.9KB
Regulatory Filings
2022-07-11 English
Neuren appoints Chief Medical Officer in United States 2 pages 155.5KB
Board/Management Information
2022-07-07 English
Notification regarding unquoted securities - NEU 7 pages 30.8KB
Share Issue/Capital Change
2022-07-07 English
AGM Chairman's Address & CEO Presentation 29 pages 678.6KB
AGM Information
2022-05-29 English
Results of Meeting 1 page 64.3KB
Declaration of Voting Results & Voting Rights Announcements
2022-05-29 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 235.9KB
Interim / Quarterly Report
2022-04-28 English
Notice of Annual General Meeting/Proxy Form 9 pages 800.4KB
AGM Information
2022-04-27 English
Virtual AGM online guide 5 pages 1.1MB
AGM Information
2022-04-27 English
Annual Report to shareholders 54 pages 1.8MB
Annual Report
2022-04-26 English
Appendix 4G 13 pages 152.4KB
Regulatory Filings
2022-04-26 English
Change in substantial holding 7 pages 222.9KB
Major Shareholding Notification
2022-04-26 English
FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial 2 pages 157.1KB
Capital/Financing Update
2022-03-24 English
FDA approval for Phelan-McDermid IND and Phase 2 trial 2 pages 158.2KB
Regulatory Filings
2022-03-22 English
Ethics approval for Angelman Phase 2 trial in Australia 2 pages 158.4KB
Regulatory Filings
2022-03-10 English
FDA approval for Angelman IND and Phase 2 trial 2 pages 160.0KB
Regulatory Filings
2022-02-24 English
Investor presentation 25 Feb 2022 30 pages 912.2KB
Investor Presentation
2022-02-24 English
Preliminary Final Report and 2021 Full Year Accounts 29 pages 503.5KB
Annual Report
2022-02-23 English
2021 Results - a transformational year for Neuren 5 pages 185.1KB
Annual Report
2022-02-23 English
Notification regarding unquoted securities - NEU 7 pages 31.4KB
Share Issue/Capital Change
2022-02-02 English
Neuren appoints Vice President, Corporate Development 2 pages 153.0KB
Board/Management Information
2022-01-31 English
Q4 2021 quarterly activity and cash flow report 9 pages 338.1KB
Interim / Quarterly Report
2022-01-30 English